Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

Clinical trial NCT07259889 · RECRUITING

Trial details

NCT number: NCT07259889
Sponsor: Guangzhou Xiling Biotechnology Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors (Phase 1)

Start date: 2025-06-16
Primary completion: 2028-06-15
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.